Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod

Travere is eyeing a collective $3 billion U.S. opportunity for Filspari thanks to a new rare kidney disease nod, plus the med's initial 2023 approval in another rare kidney indication.